Get the Stockscreener App
42.03
0.06%
-0.035
Harmony Biosciences Holdings Inc stock is traded at $42.03, with a volume of 444.77K.
It is down -0.06% in the last 24 hours and up +9.46% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
See More
Previous Close:
$42.07
Open:
$42.01
24h Volume:
444.77K
Relative Volume:
0.55
Market Cap:
$2.45B
Revenue:
$899.11M
Net Income/Loss:
$145.62M
P/E Ratio:
16.93
EPS:
2.4829
Net Cash Flow:
$322.54M
1W Performance:
-1.90%
1M Performance:
+9.46%
6M Performance:
+47.17%
1Y Performance:
+23.66%
1-Day Range:
$41.51
$42.41
1-Week Range:
$41.36
$43.49
52-Week Range:
$25.52
$43.49
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
42.03 | 2.45B | 899.11M | 145.62M | 322.54M | 2.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
522.87 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
804.27 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,003.47 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.81 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.50 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-23-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-23-26 | Downgrade | Truist | Buy → Hold |
| Feb-11-26 | Resumed | UBS | Neutral |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-17-24 | Initiated | H.C. Wainwright | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-10-24 | Initiated | UBS | Buy |
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
Harmony Biosciences (NASDAQ: HRMY) officer lines up a seven-figure stock sale - Stock Titan
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now - Eastern Progress
HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - Stocktwits
Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreement - Stocktwits
Harmony Biosciences stock holds near USD 41.86 - AD HOC NEWS
Harmony Biosciences (HRMY) executive to sell about $230K in stock - Stock Titan
Why Is Harmony Biosciences (HRMY) Up 12.1% Since Last Earnings Report? - Yahoo Finance
Harmony Biosciences to Present Encore EPX-100 Data from ARGUS Study at 16th European Epilepsy Congress - Quiver Quantitative
Harmony Biosciences Announces Poster Presentations at the 16th European Epilepsy Congress - Yahoo Finance
Harmony Biosciences stock hits 52-week high at $42.70 By Investing.com - Investing.com South Africa
Top 5 US Stocks To Buy In September 2026 - Investing.com
Harmony Biosciences stock hits 52-week high at $42.70 - Investing.com
Precision Trading with Harmony Biosciences Holdings Inc. (HRMY) Risk Zones - Stock Traders Daily
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference - Investing News Network
This Atlassian Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Sahm
HRMY Initiates Coverage On Wolfe Research -- Rating Set to Outpe - GuruFocus
Wolfe Research initiates Harmony Biosciences stock at Outperform - Investing.com
Wolfe Research initiates Harmony Biosciences stock at Outperform By Investing.com - Investing.com Canada
Virtus Advisers LLC Makes New Investment in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Tieton Capital Management LLC Takes Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Denali Advisors LLC Purchases 29,700 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Stephen M. Mollichella Net Worth (2026) - GuruFocus
Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st
Chase Investment Counsel Corp Takes $1.82 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline - MarketBeat
HRMY: Record WAKIX sales drive CNS pipeline progress, with BP-205 and new pitolisant forms advancing - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Zacks Research Downgrades Harmony Biosciences (NASDAQ:HRMY) to Hold - MarketBeat
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance
Harmony Sets Investor Appearance as CNS Strategy Advances - MyChesCo
Hennion & Walsh Asset Management Inc. Decreases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings (HRMY) Stock Analysis: Exploring an 18% Potential Upside with Strong Revenue Growth - DirectorsTalk Interviews
Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Janus Henderson Group PLC - MarketBeat
(HRMY) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Why Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Surge And Pipeline Progress - Sahm
Harmony Profit Jumps as WAKIX Revenue Climbs 30% - MyChesCo
Harmony Biosciences (NASDAQ:HRMY) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Jump And Pipeline ProgressWhat's Changed - Yahoo Finance
Harmony Biosciences (NASDAQ: HRMY) holder to sell 700,883 shares - Stock Titan
Harmony Biosciences Holdings, Inc. Just Recorded A 34% EPS Beat: Here's What Analysts Are Forecasting Next - Moomoo
First Trust Advisors LP Sells 50,805 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc (HRMY) Stock News Today - TradingKey
Harmony Biosciences Holdings Inc (HRMY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium - The Manila Times
Harmony Biosciences management plans Aug. 13 fireside chat webcast - Stock Titan
Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated (HRMY) - Seeking Alpha
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM) - The Globe and Mail
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.14%
3.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):